|
| 37583435 | Cancer Epidemiology in the Northeastern United States (2013-2017). | Cancer Res Commun | 2023 |
| 37480151 | Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-β signaling pathways in cancer. | Cell Biosci | 2023 |
| 34764459 | Connecting copper and cancer: from transition metal signalling to metalloplasia. | Nat Rev Cancer | 2022 |
| 35896617 | Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer. | Oncogene | 2022 |
| 34116144 | Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. | Ann Oncol | 2021 |
| 33741442 | Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. | Ann Oncol | 2021 |
| 34944703 | Evaluation of ATOX1 as a Potential Predictive Biomarker for Tetrathiomolybdate Treatment of Breast Cancer Patients with High Risk of Recurrence. | Biomedicines | 2021 |
| 34911956 | Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. | Nat Commun | 2021 |
| 34426581 | Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. | NPJ Breast Cancer | 2021 |
| 34016993 | Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. | NPJ Breast Cancer | 2021 |
| 32613539 | Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. | Breast Cancer Res Treat | 2020 |
| 31968251 | Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. | Cell Rep | 2020 |
| 32946924 | Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. | Ann Oncol | 2020 |
| 32934032 | Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. | Clin Cancer Res | 2020 |
| 30511901 | Personalized Nutrition in Disrupting Cancer - Proceedings From the 2017 American College of Nutrition Annual Meeting. | J Am Coll Nutr | 2019 |
| 31195996 | Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer. | BMC Cancer | 2019 |
| 31592503 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. | JCO Precis Oncol | 2019 |
| 31089928 | Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis. | Breast Cancer Res Treat | 2019 |
| 30855113 | Copper Depletion as a Therapeutic Strategy in Cancer. | Met Ions Life Sci | 2019 |
| 30999962 | Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. | Breast Cancer Res | 2019 |
| 30786188 | Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. | N Engl J Med | 2019 |
| 29706375 | Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. | Lancet Oncol | 2018 |
| 30240327 | Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. | J Clin Oncol | 2018 |
| 30153978 | Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. | Clin Breast Cancer | 2018 |
| 30007894 | A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. | Eur J Cancer | 2018 |
| 30505260 | Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme-Induced Local Retention Properties. | Adv Funct Mater | 2018 |
| 27830395 | Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. | Support Care Cancer | 2017 |
| 28356425 | Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. | Clin Cancer Res | 2017 |
| 28220020 | Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. | Oncologist | 2017 |
| 28291390 | Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. | J Clin Oncol | 2017 |
| 28945887 | Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. | Ann Oncol | 2017 |
| 28813674 | An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. | Cell Rep | 2017 |
| 28558150 | Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. | Cancer | 2017 |
| 28503956 | Sacituzumab govitecan: an antibody-drug conjugate. | Expert Opin Biol Ther | 2017 |
| 27769988 | Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. | Clin Cancer Res | 2017 |
| 26719537 | Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche. | Cancer Res | 2016 |
| 30190890 | Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i><sup>V600</sup> mutated melanoma. | Melanoma Manag | 2016 |
| 27994483 | Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. | Breast Cancer (Dove Med Press) | 2016 |
| 27180972 | Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. | Biomacromolecules | 2016 |
| 25573650 | Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. | Breast Cancer Res Treat | 2015 |
| 26413438 | Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. | Springerplus | 2015 |
| 26560033 | Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. | Nature | 2015 |
| 26290412 | Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. | Sci Transl Med | 2015 |
| 25885598 | Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. | BMC Cancer | 2015 |
| 25847941 | EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. | J Clin Oncol | 2015 |
| 25944802 | First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. | Clin Cancer Res | 2015 |
| 25720743 | Menopause is a determinant of breast adipose inflammation. | Cancer Prev Res (Phila) | 2015 |
| 25749072 | Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy. | Clin Breast Cancer | 2015 |
| 25459070 | Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy. | Clin Breast Cancer | 2015 |
| 24202699 | Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. | Lab Chip | 2014 |